AGL 37.72 Decreased By ▼ -0.22 (-0.58%)
AIRLINK 168.65 Increased By ▲ 13.43 (8.65%)
BOP 9.09 Increased By ▲ 0.02 (0.22%)
CNERGY 6.85 Increased By ▲ 0.13 (1.93%)
DCL 10.05 Increased By ▲ 0.52 (5.46%)
DFML 40.64 Increased By ▲ 0.33 (0.82%)
DGKC 93.24 Increased By ▲ 0.29 (0.31%)
FCCL 37.92 Decreased By ▼ -0.46 (-1.2%)
FFBL 78.72 Increased By ▲ 0.14 (0.18%)
FFL 13.46 Decreased By ▼ -0.14 (-1.03%)
HUBC 114.10 Increased By ▲ 3.91 (3.55%)
HUMNL 14.95 Increased By ▲ 0.06 (0.4%)
KEL 5.75 Increased By ▲ 0.02 (0.35%)
KOSM 8.23 Decreased By ▼ -0.24 (-2.83%)
MLCF 45.49 Decreased By ▼ -0.17 (-0.37%)
NBP 74.92 Decreased By ▼ -1.25 (-1.64%)
OGDC 192.93 Increased By ▲ 1.06 (0.55%)
PAEL 32.24 Increased By ▲ 1.76 (5.77%)
PIBTL 8.57 Increased By ▲ 0.41 (5.02%)
PPL 167.38 Increased By ▲ 0.82 (0.49%)
PRL 31.01 Increased By ▲ 1.57 (5.33%)
PTC 22.08 Increased By ▲ 2.01 (10.01%)
SEARL 100.83 Increased By ▲ 4.21 (4.36%)
TELE 8.45 Increased By ▲ 0.18 (2.18%)
TOMCL 34.84 Increased By ▲ 0.58 (1.69%)
TPLP 11.24 Increased By ▲ 1.02 (9.98%)
TREET 18.63 Increased By ▲ 0.97 (5.49%)
TRG 60.74 Decreased By ▼ -0.51 (-0.83%)
UNITY 31.98 Increased By ▲ 0.01 (0.03%)
WTL 1.61 Increased By ▲ 0.14 (9.52%)
BR100 11,289 Increased By 73.1 (0.65%)
BR30 34,140 Increased By 489.6 (1.45%)
KSE100 105,104 Increased By 545.3 (0.52%)
KSE30 32,554 Increased By 188.3 (0.58%)

A single-member bench of the Sindh High Court (SHC), comprising Justice Mohammad Shafi Siddiqui, through an order on Thursday overthrew the decision by the provincial health authorities to purchase costly hepatitis drug from two multinational companies (MNCs).
The bench acknowledging that this was depriving local pharma companies of level-playing ground scraped tender to buy costly hepatitis medicine from MNCs.
Justice Mohammad Shafi Siddiqui who had reserved the judgement on March 6, announcing the same on Thursday, termed the process of purchase of medicine illegal, unlawful and without legal grounds; scrapping the tender issued for purchase of medicine worth Rs 250 million.
The detailed judgement came on a petition filed by various local pharmaceutical firms against the rejection of their products used for the treatment of Hepatitis B and C.
Earlier, the court had rejected the plea by the health department for partial purchase of hepatitis medicine from multinationals on the grounds that the court was hearing the case on priority basis, therefore limited purchase could not be allowed.
The health authorities had pleaded to relax the stay order on the purchase of injection so that 25 percent of medicine costing around Rs 60.2 million could be bought for 33,000 patients, of whom some 1,800 were at terminal stage.
Advocates Faisal Siddiqui, Shahid Memon and Abdus Sattar Pirzada, the counsel for the petitioners, told the court that the government was playing games with mala fide intentions to benefit certain influential, causing great losses to public exchequer and interest of poor hepatitis patients.
They questioned as to why many leading health institutions including the government of Balochistan and the government of AJK had been purchasing and using the locally produced medicines for decades with no complaints, if they were harmful to human health.
The counsel further argued that the government had issued licences to the local national pharmaceutical firms to produce the drug, allowing it to sell the medicine in local market as well as to export it.

Copyright Associated Press of Pakistan, 2015

Comments

Comments are closed.